

AVAXIM® Junior is indicated for active immunisation against infection caused by hepatitis A virus (HAV) in children aged 1 - 15 years.1
Before you prescribe this vaccine please refer to the Prescribing Information and SmPC link. The use of Avaxim Junior should be based on official recommendations.
Summary

Fast
- AVAXIM Junior provides rapid seroprotection against hepatitis A as early as two weeks from the first dose.1
- 14 days after the first dose of vaccination more than 94% of immunocompetent individuals are protected.*2

Flexible
- AVAXIM Junior is interchangeable with other paediatric inactivated hepatitis A vaccines as a booster with flexible booster timing.1
- The booster dose can be given between 6 months and 15 years after the first dose.1

Effective
- AVAXIM Junior offers long-lasting protection against Hepatits A, up to 15 years after initial immunisation.†1,3
*Seroconversion defined as anti-HAV antibody titres rising from <20 mlU/ml (seronegative) to ≥20 mIU/ml. Monocentric, open trial evaluating Avaxim in children aged 18 months – 3 years (n=37), 4 – 8 years (n=53) and 9-15 years (n=83). Two weeks after the first dose, seroconversion was achieved by 94.6% of initially HAV-seronegative subjects aged 18 months – 3 years, 94.3% of subjects aged 4-8 years and 96.4% of subjects aged 9-15 years.2
†One study was conducted in children (N=54) aged 12 through 47 months vaccinated with 2 doses of the vaccine 6 months apart. The results showed a persistence of the antibodies for a period up to 14-15 years at levels considered as protective and do not suggest a need for new administration of the vaccine. A statistical model using the available data from this study until 14-15 years after the administration of the 2 doses of the vaccine predicts a persistence of the protective anti-HAV antibodies for at least 30 years in 87.5% of these children (estimated prediction within the 95% confidence interval CI[74.1; 94.8]).3 Another long-term persistence study was conducted in Argentina with children aged between 11 and 23 months at the time of inclusion. All children had received routine vaccination with 1 dose (Group 1: N = 436) or 2 doses (Group 2: N = 108) of hepatitis A vaccine. After 15 years of follow-up, all remaining subjects showed anti HAV antibodies concentration ≥10 mIU/mL (using ATELLICA) indicative of seroprotection for up to 15 years after 1 or 2 doses. Statistical modelling using data from HAF82 (covering Year 0 to Year 15) including natural boosting effect, predicts that 94% [89-98] of subjects having received one vaccine dose and 93% [88-97] of subjects having received two vaccine doses will have anti-HAV titers above the threshold for seroprotection for up to 40 years after the first administration.4
AVAXIM Junior is shown to be generally well tolerated in young children.
Based on data from a pooled analysis, most undesirable effects following administration of AVAXIM Junior were limited to the first few days following immunisation with spontaneous recovery.*1
The most common adverse reactions (≥10%) were injection site pain, malaise, headache and abnormal crying.1
For the full list of adverse events please refer to the AVAXIM Junior summary of product characteristics.
Adverse reactions |
Frequency after any dose |
---|---|
Blood and Lymphatic system disorder | |
Lymphadenopathy | Not known |
Immune system disorders | |
Anaphylactic reaction | Not known |
Metabolism and nutrition disorders | |
Appetite decrease | Common |
Psychiatric disorders | |
Abnormal crying | Very Common |
Irritability | Common |
Insomnia | Common |
Nervous system disorders | |
Headache | Very Common |
Vasovagal syncope in response to injection | Not known |
Convulsions with or without fever | Not known |
Gastrointestinal disorders | |
Abdominal pain | Common |
Diarrhoea | Common |
Nausea | Common |
Vomiting | Common |
Skin and subcutaneous tissue disorders | |
Rash | Uncommon |
Urticaria | Uncommon |
Musculoskeletal and connective tissue disorders | |
Arthralgia | Common |
Myalgia | Common |
General disorders and administration site conditions | |
Injection site pain | Very Common |
Malaise | Very Common |
Pyrexia | Common |
Injection site erythema | Common |
Asthenia or drowsiness | Common |
Injection site induration or oedema | Common |
Injection site haematoma | Common |
*Pooled analysis integrated data from 5458 children aged from 12 months to 15 years of age who received at least one injection of Avaxim Junior during clinical trials.1
.

References
- Avaxim Junior Summary of Product Characteristics
- Dagan R, et al. Vaccine. 1999;17(15-16):1919-25
- López, E. L, et al. Pediatr Infect Dis J. 2015; 34(4), 417-425.
- Espul, C, et al. Vaccine 2020;38(4):858-865.
MAT-XU-2301296 (v6.0) Date of preparation: August 2025